BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V

Trial Profile

BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BIOFLOW-V
  • Sponsors BIOTRONIK
  • Most Recent Events

    • 28 Aug 2017 Results from this trial were presented at the European Society of Cardiology's ESC Congress 2017 and published in The Lancet, according to a Biotronik media release.
    • 28 Aug 2017 Primary endpoint (Target lesion failure (TLF) rate at 12 months post-index procedure.) has been met, according to a Biotronik media release.
    • 28 Aug 2017 Results published in a Biotronik media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top